title: Why should regulators consider using patient preferences in benefit-risk assessment?
authors.affiliation: Department of Health Technology and Services Research, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands, j.a.vantil@utwente.nl.
authors.forename: Janine A
authors.initials: JA
authors.lastname: van Til
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Ijzerman
mesh_terms: D003661:Decision Support Techniques; D004358:Drug Therapy / Q000191:economics; D064420:Drug-Related Side Effects and Adverse Reactions; D005060:Europe; D033161:Government Regulation; D006801:Humans; D057240:Patient Preference / Q000191:economics / Q000331:legislation & jurisprudence; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration